| Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial. |
Ongoing |
Articaine |
3 |
607-43-7809 |
Qassim Regional Dental Center,The One Clinic (Buraydah) |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross over Study of Oral Deucrictibant Soft Capsule for On Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema |
Ongoing |
Deucrictibant |
3 |
PHA022121-C306 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) |
Ongoing |
Nipocalimab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) |
Ongoing |
Tirzepatide |
4 |
I8F-MC-GPIY |
Al Moosa Specialized Hospital (al ahsa), King Faisal Specialist Hospital and Research Center (Riyadh), Saudi Airlines Medical Service Center (Jeddah), King Fahad Medical City (Riyadh), Dallah Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Madinah) |
| CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
Ongoing |
Camizestrant (AZD9833) |
3 |
8535C00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment |
Ongoing |
amlitelimab |
3 |
EFC17599 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Ongoing |
Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine |
2 |
RJ19/119/J |
King Abdullah Medical Complex (Jeddah) |
| A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses |
Ongoing |
Insulin |
3 |
2023-45 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency |
Ongoing |
INZ701 |
3 |
INZ701-106 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Long-term pain and adherence observational study for Endometriosis treatment |
Ongoing |
Duphaston |
4 |
DYDR-522-0318 |
Dr.Arab Clinic |
